New Brazil data shows only 50.4% efficacy for China's CoronaVac vaccine
Published: Jan 13, 2021 1:21 AM | Updated: Jan 13, 2021 2:29 AM
A coronavirus vaccine developed by China's Sinovac Biotech was just 50.4% effective at preventing symptomatic infections in a Brazilian trial, researchers said on Tuesday, barely enough for regulatory approval and well below the rate announced last week.
The latest results are a major disappointment for Brazil, as the Chinese vaccine is one of two that the federal government has lined up to begin immunisation during the second wave of the world's second-deadliest Covid-19 outbreak.
View Comments0
Report this comment
500 characters remaining
Are you sure you want to delete this comment?
This action cannot be undone.